These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24594379)

  • 1. DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma.
    Shin KE; Ahn KJ; Choi HS; Jung SL; Kim BS; Jeon SS; Hong YG
    Clin Radiol; 2014 Jun; 69(6):e264-72. PubMed ID: 24594379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
    Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
    Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differentiation between glioma recurrence and radiation-induced brain injuries using perfusion-weighted magnetic resonance imaging].
    Wang YL; Liu MY; Wang Y; Xiao HF; Sun L; Zhang J; Ma L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):416-21. PubMed ID: 23987489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
    Xu Q; Liu Q; Ge H; Ge X; Wu J; Qu J; Xu K
    Medicine (Baltimore); 2017 Dec; 96(50):e9332. PubMed ID: 29390403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
    Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
    Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE and DSC perfusion MRI diagnostic accuracy in the follow-up of primary and metastatic intra-axial brain tumors treated by radiosurgery with cyberknife.
    Morabito R; Alafaci C; Pergolizzi S; Pontoriero A; Iati' G; Bonanno L; Gaeta M; Salpietro FM; Mormina E; Longo M; Granata F
    Radiat Oncol; 2019 Apr; 14(1):65. PubMed ID: 30992043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.
    Fink JR; Carr RB; Matsusue E; Iyer RS; Rockhill JK; Haynor DR; Maravilla KR
    J Magn Reson Imaging; 2012 Jan; 35(1):56-63. PubMed ID: 22002882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
    Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
    Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.
    Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S
    Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
    Gasparetto EL; Pawlak MA; Patel SH; Huse J; Woo JH; Krejza J; Rosenfeld MR; O'Rourke DM; Lustig R; Melhem ER; Wolf RL
    Radiology; 2009 Mar; 250(3):887-96. PubMed ID: 19244052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.
    Anzalone N; Castellano A; Cadioli M; Conte GM; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Grillea G; Vitali P; Aquino D; Terreni MR; Torri V; Erickson BJ; Caulo M
    Radiology; 2018 Jun; 287(3):933-943. PubMed ID: 29361245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach.
    Falk A; Fahlström M; Rostrup E; Berntsson S; Zetterling M; Morell A; Larsson HB; Smits A; Larsson EM
    Neuroradiology; 2014 Dec; 56(12):1031-8. PubMed ID: 25204450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
    Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
    Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.